AZD9056 (hydrochloride)

AZD9056 hydrochloride is a selective orally active inhibitor of P2X7 which plays a significant role in inflammation and pain-causing diseases.

Product Specifications

CAS Number

[345303-91-5]

UNSPSC

12352005

Hazard Statement

H302, H317, H361, H373

Target

P2X Receptor

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/AZD9056-hydrochloride.html

Purity

98.18

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 1.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC(CCCNCCCO)=CC=C1Cl)NCC2(C[C@H](C3)C4)C[C@H]4C[C@H]3C2.Cl

Molecular Formula

C24H36Cl2N2O2

Molecular Weight

455.46

Precautions

H302, H317, H361, H373

References & Citations

[1]Seeland S, et al. ATP-induced cellular stress and mitochondrial toxicity in cells expressing purinergic P2X7 receptor. Pharmacol Res Perspect. 2015 Mar;3 (2) :e00123.|[2]Elsby R, et al. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate. Eur J Pharm Sci. 2011 May 18;43 (1-2) :41-9.|[3]Hu H, et al. Blocking of the P2X7 receptor inhibits the activation of the MMP-13 and NF-κB pathways in the cartilage tissue of rats with osteoarthritis. Int J Mol Med. 2016 Dec;38 (6) :1922-1932.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 2

Isoform

P2X7 Receptor

Citation 01

ACS Appl Mater Interfaces. 2025 Feb 5;17 (5) :7521-7538.|Adv Sci (Weinh) . 2025 Nov 6:e14842.|Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870 (1) :166895.|Front Immunol. 2021 Jan 8;11:602016.|J Pharmacol Sci. 2020 Sep;144 (1) :43-51.